Ranolazine attenuation of CFA-induced mechanical hyperalgesia

Pain Medicine

Volumn 11, Issue 1, 2010, Pages 119-126

  Casey, Gregory P ^a   Roberts, Jomar S ^a   Paul, Dennis ^a   Diamond, Ivan ^b   Gould III, Harry J ^c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

Allodynia; CFA; Pain; Ranolazine

Indexed keywords

ANALGESIC AGENT; FREUND ADJUVANT; RANOLAZINE; SODIUM CHLORIDE; VOLTAGE GATED SODIUM CHANNEL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HYPERALGESIA; INFLAMMATION; MALE; MECHANICAL STIMULATION; NERVE CELL; NONHUMAN; PAIN; RAT; SODIUM CURRENT; SPINAL GANGLION; THERMAL STIMULATION; UPREGULATION;

EID: 73949155091     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00763.x     Document Type: Article

References (82)

1. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerves. J Physiol 1952, 117:500-44.
2. Benarroch EE. Sodium channels and pain. Neurology 2007, 68:233-6.
3. Catterall WA, Goldin AL, Waxman SG. International union of pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005, 57:397-409.
4. Rush AM, Cummins TR, Waxman SG. Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. J Physiol 2007, 579:1-14.
5. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain 2007, 131:243-57.
6. Devor M, Seltzer Z, Wall PD, Melzack R. The pathophysiology of damaged peripheral nerves. Textbook of Pain 1999, 129-64. In, eds., Vol. 4, Edinburgh, Churchill, Livingstone
7. Devor M, Lomazov P, Matzner O, Boivie J, Hansson P, Lindblom U. Sodium channel accumulation in injured axons as a substrate for neuropathic pain. Touch, Temperature, and Pain in Health and Disease: Mechanisms and Assessments. Progress in Pain Research and Management 1994, 207-30. In, eds., Vol. 3, Seattle, IASP Press
8. Gould HJ, Gould TN, Paul D. Development of inflammatory hypersensitivity and the augmentation of sodium channels in rat dorsal root ganglia. Brain Res 1999, 824:296-9.
9. Gould HJ, Gould TN, England JD. A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res 2000, 854:19-29.
10. Gould HJ, Soignier RD, Nolan P. Ibuprofen blocks changes in Nav 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant-induced inflammation in rat. J Pain 2004, 5:270-80.
11. Kral MG, Xiong Z, Study RE. Alteration of Na+ currents in dorsal root ganglion neurons from rats with a painful neuropathy. Pain 1999, 81:15-24.
12. Waxman SG, Cummins TR, Dib-Hajj SD, Black JA. Voltage-gated sodium channels and the molecular pathogenesis of pain: A review. J Rehabil Res Dev 2000, 37:517-28.
13. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 2004, 108:237-47.
14. Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J Neurosci 1997, 17:3503-14.
15. Dib-Hajj S, Black JA, Felts P, Waxman SG. Down-regulation of transcripts for Na channel α-SNS in spinal sensory neurons following axotomy. Proc Natl Acad Sci U S A 1996, 93:14950-4.
16. Dib-Hajj SD, Black JA, Cummins TR. Rescue of α-SNS sodium channel expression in small dorsal root ganglion neurons after axotomy by nerve growth factor in vivo. J Neurophysiol 1998, 79:2668-76.
17. Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc Natl Acad Sci USA 1998, 95:8963-8.
18. Gold MS. Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia. Proc Natl Acad Sci USA 1999, 96:7645-9.
19. Gold MS, Reichling DB, Shuster MJ, Levine JD. Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors. Proc Natl Acad Sci USA 1996, 93:1108-12.
20. Gould HJ, England JD, Liu ZP, Levinson SR. Sodium channel augmentation in response to pain induced by chronic inflammation. Am Pain Soc 1997, 16:99.
21. Gould HJ, England JD, Liu ZP, Levinson SR. Sodium channel augmentation in response to inflammation induced by complete Freund's adjuvant. Brain Res 1998, 802:69-74.
22. Novakovic SD, Tzoumaka E, McGivern JG. Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J Neurosci 1998, 18:2174-87.
23. Porreca F, Lai J, Bian D. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci USA 1999, 96:7640-4.
24. Tanaka M, Cummins TR, Ishikawa K. SNS Na+ channel expression increases in dorsal root ganglion neurons in the carrageenan inflammatory pain model. Neuroreport 1998, 9:967-72.
25. Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic, but not adult spinal sensory neurons and is reexpressed following axotomy. J Neurophysiol 1994, 72:466-70.
26. Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci USA 1999, 96:7635-9.
27. England JD, Happel LT, Kline DG. Sodium channel accumulation in humans with painful neuromas. Neurology 1996, 47:272-6.
28. Cox JJ, Reimann F, Nicholas AK. An SNC9A channelopathy causes congenital inability to experience pain. Nature 2006, 444:894-8.
29. Dib-Hajj SD, Rush AM, Cummins TR. Gain-of-function mutation in Nav 1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005, 128:1847-54.
30. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Nav 1.7 and human pain disorders. Trends Neurosci 2007, 30:555-63.
31. Drenth JPH, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 2007, 117:3603-9.
32. Fertleman CR, Baker MD, Parker KA. SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 2006, 52:767-74.
33. Goldberg YP, MacFarlane J, MacDonald ML. Loss-of-function mutations in the Nav 1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 2007, 71:311-9.
34. Han C, Rush AM, Dib-Hajj SD. Sporadic onset of erythermalgia: A gain-of-function mutation in Nav 1.7. Ann Neurol 2006, 59:553-8.
35. Harty TP, Dib-Hajj SD, Tyrrell L. Nav 1.7 mutant A863P in erythromelalgia: Effects of altered activation and steady-state inactivation of excitability of nociceptive dorsal root ganglion neurons. J Neurosci 2006, 26:12566-75.
36. Nassar MA, Stirling LC, Forlani G. Nociceptor-specific gene deletion reveals a major role for Nav 1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA 2004, 101:12706-11.
37. Novella SP, Hisama FM, Dib-Hajj SD, Waxman SG. A case of inherited erythromelalgia. Nat Clin Pract 2007, 3:229-34.
38. Waxman SG. A channel sets the gain on pain. Nature 2006, 444:831-2.
39. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syndrome enters the molecular era. Ann Neurol 2005, 57:785-8.
40. Waxman SG, Dib-Hajj SD. Erythromelalgia: Molecular basis for an inherited pain syndrome. Trends Mol Med 2005, 11:555-62.
41. Yang Y, Wang Y, Li S. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004, 41:171-4.
42. England JD, Gould HJ, Liu ZP, Koszowski AG, Levinson SR. Inflammation induces a rapid upregulation of the novel sodium channel, PN1, in sensory neurons. Neurology 1998, 50(4):A184. suppl
43. Gould HJ, England JD, Paul D, Krames E, Reig E. The modulation of sodium channels during inflammation. Proc Worldwide Pain Conference 2000, 27-34. In, eds., Bologna, Italy, Monduzzi Editore, International Proceedings Division
44. Marx C, Sweeney M. Mechanism of action of ranolazine. Arch Intern Med 2006, 166:1325-6.
45. Nash DT. The case for medical treatment in chronic stable coronary artery disease. Arch Intern Med 2005, 165:2587-9.
46. Pham DQ, Mehta M. Ranolazine: A novel agent that improves dysfunctional sodium channels. Int J Clin Pract 2007, 61:864-72.
47. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine. Heart 2006, 92:6-14.
48. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008, 44:954-67.
49. Haufe V, Camacho JA, Dumaine R. Expression pattern of neuronal and skeletal muscle voltage-gated Na+ channels in the developing mouse heart. J Physiol 2005, 564:683-96.
50. Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol (Lond) 1996, 497:337-47.
51. Ju YK, Gage PW, Saint DA. Tetrodotoxin-sensitive inactivation-resistant sodium channels in pacemaker cells influence heart rate. Pflugers Arch 1996, 431:868-75.
52. Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxin-sensitive, Nav 1.7, and tetrodotoxin-resistant, Nav 1.8, Na+ channels by ranolazine. Channels 2008, 2:449-60.
53. Wang GK, Calderon J, Wang S-Y. State- and use-dependent block of muscle Nav 1.4, and neuronal Nav 1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol 2008, 73:940-8.
54. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 2006, 318:214-22.
55. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac " late sodium current" Pharmacol Ther 2008, 119:326-39.
56. Hargreaves K, Dubner R, Brown R, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.
57. Lewin GR, Ritter AM, Mendell LM. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci 1993, 13:2136-48.
58. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 1994, 6:1903-12.
59. Gould HJ, Garrett C, Donahue RR. Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol 2009, in press
60. Sossalla S, Wagner S, Rasenack EC. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008, 45:32-43.
61. Baetz D, Bernard M, Pinet C. Different pathways for sodium entry in cardiac cells during ischemia and early reperfusion. Mol Cell Biochem 2003, 242:115-20.
62. Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 2008, 294:H2031-9.
63. Reddix RA, Ma Q, Liu Z. Peripheral nerve (PN1) sodium channels are upregulated in dorsal root ganglion neurons in a rat model of experimental colitis. 2001, Paper presented at the 31st Annual Meeting of the Society for Neuroscience (SfN), San Diego, CA
64. Morris G, Jeansonne BG, Paul D, Gould HJ. Sodium channel augmentation following tooth pulp injury. 2002, Paper presented at the 10th World Congress of Pain (IASP), San Diego, CA
65. Djouhri L, Newton R, Levinson SR. Sensory and electrophysiological properties of guinea-pig sensory neurons expressing Nav 1.7 (PN1) Na+ channel α subunit protein. J Physiol 2003, 546:565-76.
66. Gould HJ. Complete Freund's adjuvant-induced hyperalgesia: A human perception. Pain 2000, 85:301-3.
67. Brain SD. Sensory neuropeptides: Their role in inflammation and wound healing. Immunopharmacology 1997, 37:133-52.
68. Brain SD. New feelings about the role of sensory nerves in inflammation. Nat Med 2000, 6:134-5.
69. Luger TA. Neuromediators-a crucial component of the skin immune system. J Dermatol Sci 2002, 30:87-93.
70. McGillis JP, Organist ML, Payan DG. Substance P and immunoregulation. Fed Proc 1987, 46:196-9.
71. Pincelli C, Fantini F, Giannetti A. Neuropeptides and skin inflammation. Dermatology 1993, 187:153-8.
72. Markenson JA. Mechanisms of chronic pain. Am J Med 1996, 101:6S-18S.
73. DiMarco E, Marchisio PC, Bondanza S. Growth-regulated synthesis and secretion of biologically active nerve growth factor by human keratinocytes. J Biol Chem 1991, 266:21718-22.
74. Kawamoto K, Matsuda H. Nerve growth factor and wound healing. Prog Brain Res 2004, 146:369-84.
75. Mammoto T, Seerattan RA, Paulson KD. Nerve growth factor improves ligament healing. J Orthop Res 2008, 26:957-64.
76. Schaffer M, Beiter T, Becker HD, Hunt TK. Neuropeptides: Mediators of inflammation and tissue repair? Arch Surg 1998, 133:1107-16.
77. Weihe E, Nohr D, Muller S. The tachykinin neuroimmune connection in inflammatory pain. Ann N Y Acad Sci 1991, 632:283-95.
78. Gould HJ, Gould TN, Reeb SC, Paul D. The effect of gabapentin on inflammatory pain in rats. Analgesia 1997, 3:131-9.
79. Gould HJ, Gould TN, Paul D. The effect of gabapentin on carrageenan-induced hyperalgesia. Analgesia 2002, 6:513-21.
80. Bonica JJ, Bonica JJ. Anatomic and physiologic basis of nociception and pain. The Management of Pain 1990, 28-94. In, ed., Vol. 2, Philadelphia, PA, Lea & Febiger
81. Andrew D, Greenspan JD. Peripheral coding of tonic mechanical cutaneous pain: Comparison of nociceptor activity in rat and human psychophysics. J Neurophysiol 1999, 82:2641-8.
82. Andrew D, Greenspan JD. Mechanical and heat sensitization of cutaneous nociceptors after peripheral inflammation in the rat. J Neurophysiol 1999, 82:264-56.